AlphAIAlphAI — Financial news for AI agents
investing.comOCT 12 min read$TEVA

TD Cowen initiates Teva Pharma stock with buy rating on pipeline

TD Cowen initiated coverage on Teva Pharmaceutical (TEVA) with a buy rating and $55 price target, citing its pipeline and growth prospects. TEVA is near its 52-week high and has returned 98% over the past year. The FDA accepted Teva's NDA for ecopipam, and Moody's upgraded the company to investment grade. Other analysts also see growth potential in Teva's products.

Original reporting
investing.com
Published Oct 1, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TEVA
Bullish
high confidence
Mentioned
$TEVA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TEVABullishHigh
01

Why it matters

The combined analyst coverage and credit upgrade reinforce a bullish case for Teva.

02

Market read

New analyst coverage and credit upgrade provide fresh catalyst for TEVA.

03

What to watch

Upcoming FDA decisions and competitive pressures could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

TD Cowen's initiation follows recent FDA acceptance of Teva's new drug application and Moody's upgrade to investment grade.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

TD Cowen initiated coverage on Teva with a buy rating and a $55 price target, citing pipeline advancements and recent FDA acceptance of a new drug application.

Expected impact

upward pressure as investors price in the new $55 target and pipeline progress

Evidence & confidence

Buy rating and a 39% upside target are fresh analyst actions that can move the stock immediately.

Market effects

Sector

Positive outlook may lift other generic and biosimilar drug makers.

Regional

Potentially supportive for US pharma sector.

Global

Limited to pharma investors, no broad market effect.

Counterpoint

What could challenge this read

Some investors may question the valuation given Teva's debt load.

Key entities

  • analyst
    TD Cowen

    Initiated coverage with buy rating.

  • rating_agency
    Moody's

    Upgraded Teva to investment grade.

Read at source← All news

Related articles

OCT 1
$TEVAMed

Teva Pharmaceutical and Samsung Bioepis Forge Global Biosimilar

Teva Pharmaceutical (TEVA) and Samsung Bioepis agreed to develop and commercialize up to six biosimilar candidates, including SB41 and SB44. Teva will handle sales in key markets, while Samsung Bioepis leads development. TEVA is trading at $39.60, deemed 137.8% overvalued by GF Value™, with a GF Score™ of 60. Insiders sold $14.6M in shares over the past year.

gurufocus.com2 min
SEP 30
$TEVALow

Teva Pharmaceutical Names Serge Rogasik CEO of TAPI Division, Ti

Teva Pharmaceutical (TEVA) appointed Serge Rogasik as CEO of its Technology & API Services division. The company's stock is trading at $39.60, 137.8% above its GF Value™ of $16.65, indicating significant overvaluation. TEVA has a GF Score™ of 60, with strengths in profitability and momentum but weaknesses in financial strength, growth, and valuation. Insiders have sold $14.6 million in shares over the past year with no insider buying.

gurufocus.com2 min
SEP 30
$TEVAMedAI 8/10

Denosumab Biosimilar Approved For Existing Oncology Indications

The FDA approved Teva's Degevma (denosumab-adet) as a biosimilar to Xgeva (denosumab) for oncology-related bone disease indications. This is Teva's second biosimilar approval in 2026, following Ponlimsi (denosumab-adet) for osteoporosis. The approval covers prevention of skeletal-related events, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.

targetedonc.com2 min
SEP 30
$TEVAHighAI 9/10

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Teva Pharmaceutical Industries announced FDA approval of denosumab-adet (Degevma), a biosimilar to Amgen's Xgeva, for multiple indications including bone metastases and giant cell tumor. Approval was based on comparable efficacy and safety data. Teva anticipates U.S. launch in coming months, marking its second FDA-approved biosimilar in 2026.

biopharminternational.com2 min
SEP 30
$TEVAMedAI 9/10

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy

The FDA approved Teva Pharmaceuticals' denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva) for multiple indications, including skeletal-related events in cancer patients. This follows the March 2026 approval of denosumab-adet (Ponlimsi) as a biosimilar to denosumab (Prolia). Teva expects to launch both biosimilars in the U.S. soon, according to the company.

onclive.com2 min